Indomethacin is the most frequently used pharmacological agent for closure of a patent ductus arteriosus (PDA) in premature infants. However, reports of complications, particularly, necrotizing enterocolitis (NEC) and isolated gastrointestinal perforation have generated concerns about the use of this medication.
BACKGROUND
A patent ductus arteriosus (PDA) is commonly present in premature infants with respiratory distress syndrome. [1] [2] [3] [4] Infants with significant left-to-right shunting through the ductus are at increased risk for necrotizing enterocolitis (NEC), bronchopulmonary dysplasia, intraventricular hemorrhage (IVH), and death. [5] [6] [7] [8] [9] [10] Closure of the ductus before hemodynamically significant left-to-right shunting occurs has been shown to improve outcomes. 6, 11 Both pharmacological treatment and surgical intervention have been successfully used to close a hemodynamically significant ductus in premature infants. Indomethacin, a prostaglandin synthase inhibitor, is the most frequently used pharmacological agent for closure of a PDA in the premature infant. However, reports of complications, particularly, NEC and isolated gastrointestinal perforation, have generated concerns about the use of indomethacin therapy for closure of a PDA. [12] [13] [14] [15] [16] [17] [18] [19] [20] Hypoperfusion of the gastrointestinal tract appears to be an important contributing factor to the development of NEC in premature infants with a hemodynamically significant ductus arteriosus. Indomethacin induces a significant reduction in mesenteric blood flow, which further compromises bowel perfusion in the presence of a hemodynamically significant PDA and provides a rationale for the association between PDA, NEC, gastrointestinal complications and the use of indomethacin. 21, 22 Although this rationale seems compelling, studies of indomethacin prophylaxis and randomized control trials of indomethacin therapy for a hemodynamically significant PDA have failed to identify any increased risk for NEC. 23, 24 However, an increased risk for isolated gastrointestinal perforation, presumably a separate entity to NEC, has been observed in several studies where infants have received prophylactic indomethacin, particularly when indomethacin prophylaxis is used in combination with early dexamethasone treatment. [18] [19] [20] In this retrospective study, we compared the incidence of NEC, NEC-related gastrointestinal complications and isolated gastrointestinal perforation among a large cohort of low birth-weight (LBW) infants with a hemodynamically significant PDA who were treated, with either indomethacin alone (I), surgical ligation alone (L), or indomethacin followed by surgical ligation (I-L). The study tested the hypothesis that premature infants pharmacologically treated with indomethacin for a hemodynamically significant PDA would have a comparable incidence of NEC, NEC-related gastrointestinal complications and isolated gastrointestinal perforation to those infants who were treated by surgical ligation of the PDA.
METHODS
The medical records of all premature infants who underwent treatment, either pharmacological or surgical, for a hemodynamically significant ductus over a 4-year period (1995 to 1998) were reviewed. The institutional review board for human subject research at Baylor College of Medicine approved the study. Prophylactic indomethacin therapy was not used in our institution during the study period. PDA was diagnosed by bedside Doppler echocardiography and considered hemodynamically important, if echocardiographic features of a significant left-to-right shunt were present. The indications for testing were based on clinical factors including, murmur, bounding pulses, hyperactive precordium, increased need for supplemental oxygen, and pulmonary edema. All infants with a hemodynamically significant PDA were treated with either indomethacin or surgical ligation or both. The initial choice of treatment was based on our institutional guidelines that recommend the use of indomethacin for a premature infant r1500 g with echocardiographic evidence of a clinically significant PDA and no contraindications to treatment, and the discretion of the attending neonatologist. At the time of the study, surgical ligation of the PDA was the preferred treatment option for a number of the attending neonatologists (L group of study patients F surgical ligation alone). Infants who failed medical therapy subsequently underwent surgical ligation (I-L group of study patients F indomethacin followed by surgical ligation). NEC was defined and classified according to Kliegman and Walsh. 25 Only infants with definite NEC, stage IIA or greater, were included in the study. In stage IIA disease, the diagnosis of NEC was confirmed by the presence of pneumatosis intestinalis on abdominal radiographs. Infants who developed NEC prior to treatment for the PDA were excluded. Isolated gastrointestinal perforation with no other clinical, radiographic, or laboratory evidence of NEC was recorded separately. Head ultrasonography was performed in almost all cases after either indomethacin or surgical treatment of the ductus. IVH was classified according to Papile et al. 26 Perinatal and postnatal risk factors including maternal history, birth history, gestational age, neonatal respiratory illness, congenital heart disease, umbilical catheter placement, and feeding history were examined.
During the study period, indomethacin was administered intravenously (0.2 mg/kg/dose) every 12 hour for four doses. If the PDA was not closed after the initial four-dose course and no contraindications to treatment were present, a 5th or 6th dose of 0.2 mg/kg was given. Rarely were more than six doses prescribed. Following medical treatment, successful closure of the ductus was confirmed by bedside Doppler echocardiography. Infants whose ductus failed to close after medical treatment underwent surgical ligation. All ligations were performed in the neonatal intensive care unit under general anesthesia. One or two clips were placed across the ductus; one PDA was ligated using a silk tie.
Data analysis
Outcomes compared morbidity and mortality from NEC and gastrointestinal-related complications, including NEC-related complications, surgery for NEC, and isolated gastrointestinal perforation between PDA treatment groups (I, L, and I-L). Most data are expressed as means±SD. Data were analyzed with one-or two-way analysis of variance (ANOVA), as indicated. When the two-way ANOVA determined a statistically significant difference or an interaction, a subsequent one-way ANOVA was carried out with appropriate post hoc testing. All analyses were performed using SPSS for windows (SPSS version 7.0 Chicago, IL). Statistical significance was attributed to pr0.05.
RESULTS
In all, 230 premature infants were treated for a hemodynamically significant PDA during the study period. Six infants developed NEC before treatment and were excluded from the study. All of these infants were larger (BW 1230±230), had greater gestational ages (28.1±2.1), and were treated later for their PDA (DOL 20±11) than the 224 infants who were included in the study. The gestational age of the study infants ranged from 21 to 32 weeks (26.2±2.1) and the birth weight ranged from 320 to 1450 g (870±246 g). Surgical ligation of the PDA was the primary treatment choice by the attending neonatologists for 39 (78%) of the infants in the L group. Relative contraindications to indomethacin treatment (renal insufficiency-serum creatinine >2 mg/l, platelets count <60,000, or bleeding diathesis) existed in 11 (22%) of the infants who were primarily treated by surgical ligation. No differences in birth weight, gestation age, or neonatal illness were observed between infants in the L group who underwent surgical ligation of the PDA either as a primary treatment choice or because of contraindication to indomethacin treatment (data not shown). Of the 224 infants included in the study, 108 (48.2%) were treated with I, 50 (22.3%) by L, and 66 (29.5%) infants and were treated with I-L. The patient characteristics in the three treatment groups were similar in terms of BW, Apgar scores, antenatal steroid use, surfactant use, ventilator support, supplemental oxygen use, umbilical line placement, and presence of congenital heart disease ( Table 1) . Gestational age were lower in the I-L group compared to the I group. In addition, infants in the L group were treated later and had higher supplemental oxygen needs prior to PDA closure than either the I or I-L group. However, these differences were mostly related to the time delay of surgical intervention and all other manifestations of neonatal illness including major morbidities were similar between the groups (Table 2) . Of the infants who died, no differences in BW, gestational age, or major morbidities were observed between groups (Table 2) . However, more deaths attributed to sepsis occurred in the L group (68% deaths) than in either the I (27% deaths) or the I-L group (54% deaths). No ligation-related deaths occurred in either the L or I-L group.
The incidence of NEC was similar in each of the PDA treatment groups (Table 2) . NEC occurred in 14 (13%) of the I group, seven (14%) of the L group, and in eight (12%) of the I-L group. The average age of NEC onset was not different among PDA treatment groups. There were no differences between groups in the percentage of infants being fed before the diagnosis of NEC. The number of NEC-related complications including, gastrointestinal perforation, surgery for NEC, and NEC-related deaths were also similar among groups. Isolated gastrointestinal perforation, deemed unrelated to NEC, occurred with similar frequency in each group.
In total, 20% of the I group and 31% of the I-L group received greater than four doses of indomethacin. In the I group, eight (7%) infants received a total of five doses, 11 (10%) infants received a total of six doses, and three (3%) infants got a total of eight doses, whereas in the I-L group, eight (12%) infants received a total of five doses, eight (12%) received a total of six doses, and five (7%) infants got a total of eight doses. However, no differences in the incidence of NEC, NEC-related gastrointestinal complications or isolated gastrointestinal perforation were observed between infants exposed to more or less than four doses of indomethacin in either the I or I-L group (data not shown). In addition, when we compared the data on all infants exposed to indomethacin (combined I and I-L groups) to the infants in the L group, no differences in the incidence of NEC, NEC-related complications, or isolated intestinal perforation were observed (data not shown). 
DISCUSSION
In this study, where 174 (combined I and I-L groups) LBW infants received intravenous indomethacin, we observed no differences in the rate of NEC, NEC-related gastrointestinal complications, or isolated gastrointestinal perforation among infants who had a PDA closed with either indomethacin alone, surgical ligation alone or indomethacin treatment followed by surgical ligation. The findings from our study do not support previous reports of an increased risk for NEC or NEC-related gastrointestinal complications following indomethacin treatment for a PDA. 12, 13, 17 Our findings are consistent with studies of indomethacin prophylaxis and randomized control trials of indomethacin therapy for a PDA that also failed to identify and increased risk for NEC. 23, 24 In the only other study to directly address the association of indomethacin treatment for a PDA and NEC, Grosfeld et al. 12 observed clinical evidence of NEC in 35% of 252 premature infants with a symptomatic PDA treated with indomethacin (0.2 mg/kg intravenously every 12 hour for three doses, and further courses if the PDA persisted), and bowel perforation occurred in 30% of these cases. Although the infants in our study were of similar size and gestational age, and received a comparable indomethacin treatment course we did not observe a higher rate of NEC among infants who had a PDA closed with indomethacin. One explanation for this difference may be related to different criteria for inclusion as an NEC case. In our study, only infants with proven NEC were included, whereas infants with both specific and nonspecific gastrointestinal findings were included in Grosfeld's study.
Several observational studies have compared the complications of indomethacin therapy versus surgical ligation of the ductus. 13, 27, 28 Although none of them specifically investigated NEC as a complication, an association between indomethacin therapy and NEC was observed in some studies 13, 27 but not in others. 28 In the largest of these reports, Koehne et al 28 retrospectively investigated complications of surgical ligation and indomethacin treatment for a PDA in 156 premature infants over a 10-year period (1987 to 1998), and observed no differences in the rate of NEC between infants who had their ductus closed, either with indomethacin (67 infants), surgical ligation (55 infants), or indomethacin followed by surgical ligation (34 infants). Although the NEC-related findings from this study are comparable to the observations from our study, it is difficult to compare the two studies, as a large number of the infants in Koehne's study (>30%) were treated with indomethacin intramuscularly, antenatal steroid exposure was low, and only 60% of the infants received surfactant, representing patient populations and treatment practices not commonly encountered in present-day neonatal intensive care units.
The incidence of proven NEC (stage IIA or greater), at 12 to 14%, in our study is comparable with recently reported outcome data on LBW infants. 3, 4, 29, 30 In addition, the rate of NEC in our study infants is also comparable to the overall incidence of NEC from our unit during the study period. However, since all infants in our study had echocardiographic evidence of a hemodynamically significant PDA we may have expected a higher overall incidence of NEC. One possible explanation for not observing this is the timing of the PDA closure in our study. Early PDA closure is associated with a lower incidence of NEC and most of the infants in our study had their PDA closed early; with indomethacin treatment initiated on day 4 of life and surgical ligation occurring on day 9 of life. 6 Other clinical findings associated with NEC, including, the percentage of infants on feeds prior to NEC, and the average age of NEC onset were equivalent to recent reports on NEC in LBW infant populations. 30 The incidence of isolated intestinal perforation in our study, presumably a separate entity to NEC, was lower than has been observed in other reports. 18, 20 Only six of the 224 study infants (2.7%) developed an isolated intestinal perforation. None of these infants had any clinical or radiological signs of NEC. Although prophylactic indomethacin alone or in combination with early dexamethasone treatment is associated with a significant increased risk for intestinal perforation, [18] [19] [20] the data supporting an association between isolated intestinal perforation and indomethacin therapy for a hemodynamically significant PDA are limited.
14-17 While our study found no differences in the incidence of isolated intestinal perforation between infants treated with either indomethacin or surgical ligation for a hemodynamically significant PDA, the interpretation of these data is limited by the small number of infants who developed these complications. Another limitation of these data is that we only investigated indomethacin as a single variable and did not examine potential corisk factors such as postnatal steroids. Nevertheless, it is interesting that even when we combined the data from all the infants exposed to indomethacin (combined I and I-L groups) or assessed the data from infants exposed to prolonged treatment courses, no relation between indomethacin exposure and isolated intestinal perforation could be identified.
In summary, in this large retrospective study, the rate of NEC and NEC-related gastrointestinal complications was similar among LBW premature infants following closure of a significant PDA with either indomethacin treatment alone, surgical ligation alone or indomethacin treatment followed by surgical ligation. Although the retrospective study design somewhat limits the interpretation of these data, the strength of this investigation lies in the large number of LBW infants who were exposed to indomethacin. Therefore, we conclude that in this large retrospective study, indomethacin treatment for a significant PDA in premature infants was not associated with a greater risk for NEC or NEC-related gastrointestinal complications than surgical ligation.
